Total Payments
$399.68
2021 Payments
$87.06
Companies
7
Transactions
20
Medicare Patients
61,473
Medicare Billing
$6.8M
Payment Breakdown by Category
Food & Beverage$300.68 (75.2%)
Education$99.00 (24.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $300.68 | 19 | 75.2% |
| Education | $99.00 | 1 | 24.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $120.25 | 8 | $0 (2020) |
| Kite Pharma, Inc. | $102.63 | 6 | $0 (2021) |
| Amgen Inc. | $99.00 | 1 | $0 (2017) |
| Janssen Pharmaceuticals, Inc | $38.42 | 2 | $0 (2018) |
| Epizyme, Inc., | $14.74 | 1 | $0 (2021) |
| Spectrum Pharmaceuticals Inc. | $13.39 | 1 | $0 (2017) |
| Kyowa Kirin, Inc. | $11.25 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $87.06 | 5 | Kite Pharma, Inc. ($72.32) |
| 2020 | $41.99 | 3 | Kite Pharma, Inc. ($30.31) |
| 2019 | $42.32 | 3 | Novartis Pharmaceuticals Corporation ($31.07) |
| 2018 | $99.30 | 6 | Novartis Pharmaceuticals Corporation ($60.88) |
| 2017 | $129.01 | 3 | Amgen Inc. ($99.00) |
All Payment Transactions
20 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/08/2021 | Epizyme, Inc., | TAZVERIK (Drug) | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2021 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $17.68 | General |
| 06/22/2021 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $19.87 | General |
| 05/07/2021 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $17.28 | General |
| 02/22/2021 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $17.49 | General |
| 11/04/2020 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Food and Beverage | In-kind items and services | $11.68 | General |
| Category: ONCOLOGY | ||||||
| 11/03/2020 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $14.54 | General |
| 08/31/2020 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $15.77 | General |
| 07/09/2019 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug), TASIGNA | Food and Beverage | In-kind items and services | $13.34 | General |
| Category: ONCOLOGY | ||||||
| 02/20/2019 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $17.73 | General |
| Category: ONCOLOGY | ||||||
| 02/07/2019 | Kyowa Kirin, Inc. | SANCUSO (Drug), POTELIGEO | Food and Beverage | In-kind items and services | $11.25 | General |
| Category: ANTIEMETIC - 5HT3 INHIBITOR | ||||||
| 11/09/2018 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $26.76 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 07/30/2018 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $11.66 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 04/09/2018 | Novartis Pharmaceuticals Corporation | RECLAST (Drug) | Food and Beverage | In-kind items and services | $12.30 | General |
| Category: BONE | ||||||
| 02/26/2018 | Novartis Pharmaceuticals Corporation | RYDAPT (Drug) | Food and Beverage | In-kind items and services | $19.51 | General |
| Category: HEMATOLOGY | ||||||
| 01/31/2018 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $12.91 | General |
| Category: ONCOLOGY | ||||||
| 01/09/2018 | Novartis Pharmaceuticals Corporation | JADENU (Drug), PROMACTA | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: HEMATOLOGY | ||||||
| 10/31/2017 | Novartis Pharmaceuticals Corporation | RYDAPT (Drug) | Food and Beverage | In-kind items and services | $16.62 | General |
| Category: HEMATOLOGY | ||||||
| 10/25/2017 | Spectrum Pharmaceuticals Inc. | Zevalin (Drug) | Food and Beverage | In-kind items and services | $13.39 | General |
| Category: Not Applicable | ||||||
| 05/09/2017 | Amgen Inc. | — | Education | In-kind items and services | $99.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 87 | 14,016 | 122,785 | $6.1M | $1.1M |
| 2022 | 111 | 17,034 | 282,896 | $11.1M | $2.1M |
| 2021 | 98 | 16,851 | 304,028 | $12.2M | $2.2M |
| 2020 | 89 | 13,572 | 147,034 | $8.4M | $1.4M |
Total Patients
61,473
Total Services
856,743
Medicare Billing
$6.8M
Procedure Codes
385
All Medicare Procedures & Services
385 procedure records from CMS Medicare Utilization — Page 2 of 16
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 207 | 598 | $35,880 | $11,037 | 30.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 98 | 173 | $86,500 | $10,541 | 12.2% |
| 83540 | Iron level | Office | 2023 | 599 | 1,447 | $101,290 | $9,103 | 9.0% |
| 83550 | Iron binding capacity | Office | 2023 | 525 | 1,008 | $126,000 | $8,555 | 6.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 229 | 661 | $125,590 | $8,329 | 6.6% |
| 84100 | Phosphate level | Office | 2023 | 664 | 1,792 | $89,600 | $8,287 | 9.2% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 22 | 27 | $15,660 | $7,072 | 45.2% |
| 84550 | Uric acid level, blood | Office | 2023 | 626 | 1,569 | $78,450 | $6,920 | 8.8% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 24 | 120 | $27,120 | $6,778 | 25.0% |
| 84165 | Protein measurement, serum | Office | 2023 | 294 | 597 | $35,820 | $6,276 | 17.5% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 121 | 304 | $21,280 | $6,199 | 29.1% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 56 | 173 | $34,600 | $5,458 | 15.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 41 | 53 | $15,900 | $4,375 | 27.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 39 | 148 | $17,760 | $4,119 | 23.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 18 | 63 | $26,460 | $4,004 | 15.1% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 72 | 105 | $19,950 | $3,775 | 18.9% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 16 | 17 | $10,200 | $3,202 | 31.4% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 14 | 18 | $15,746 | $2,912 | 18.5% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 72 | 154 | $7,700 | $2,775 | 36.0% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 76 | 220 | $17,600 | $2,724 | 15.5% |
| 84403 | Testosterone (hormone) level, total | Office | 2023 | 40 | 103 | $30,900 | $2,605 | 8.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 56 | 167 | $15,865 | $2,481 | 15.6% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 19 | 27 | $10,800 | $2,245 | 20.8% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 32 | 12,804 | $16,000 | $2,059 | 12.9% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 73 | 107 | $10,700 | $2,027 | 18.9% |
About Dr. Gurmohan Syali, MD
Dr. Gurmohan Syali, MD is a Medical Oncology healthcare provider based in E Setauket, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/22/2005. The National Provider Identifier (NPI) number assigned to this provider is 1932195138.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gurmohan Syali, MD has received a total of $399.68 in payments from pharmaceutical and medical device companies, with $87.06 received in 2021. These payments were reported across 20 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($300.68).
As a Medicare-enrolled provider, Syali has provided services to 61,473 Medicare beneficiaries, totaling 856,743 services with total Medicare billing of $6.8M. Data is available for 4 years (2020–2023), covering 385 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location E Setauket, NY
- Active Since 09/22/2005
- Last Updated 03/24/2014
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1932195138
Products in Payments
- XARELTO (Drug) $38.42
- RYDAPT (Drug) $36.13
- KISQALI (Drug) $30.64
- JADENU (Drug) $16.16
- TAZVERIK (Drug) $14.74
- Zevalin (Drug) $13.39
- PROMACTA (Drug) $13.34
- RECLAST (Drug) $12.30
- PIQRAY (Drug) $11.68
- SANCUSO (Drug) $11.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.